Only in Titles

Search results for: IgG

paperclip

Error loading info... Pleas try again later.
paperclip

Error loading info... Pleas try again later.
paperclip

Error loading info... Pleas try again later.
paperclip

#32453570   2020/05/26 To Up

Middle level IM-MS and CIU experiments for improved therapeutic immunoglobulin subclass fingerprinting.

Most of the current FDA and EMA approved therapeutic monoclonal antibodies (mAbs) are based on humanized or human IgG1, 2 or 4 subclasses and engineered variants. On the structural side, these subclasses are characterized by specific inter-chains disulfide bridge connections. Different analytical techniques have been reported to assess intact IgGs subclasses, with recently special interest in native ion mobility (IM) and collision induced unfolding (CIU) mass spectrometry (MS). However, these two techniques exhibit significant limitations to differentiate mAb subclasses at the intact level. In the present work, we aimed at developing a unique IM-MS-based approach for the characterization of mAb subclasses at the middle level. Upon IdeS-digestion, the unfolding patterns of the F(ab')2 and Fc domains were simultaneously analyzed in a single run to provide deeper structural insights of the mAb scaffold. The unfolding patterns associated with the F(ab')2 domains are com-pletely different in terms of unfolding energies and number of transitions. Thereby, F(ab')2 regions are the diagnostic domain to provide specific unfolding signatures to differentiate IgG subclasses and provide more confident subclass categorization than CIU on intact mAbs. In addition, the potential of middle-level CIU was evaluated through the characterization of ecu-lizumab, a hybrid therapeutic IgG2/4 mAb. The unfolding signatures of both domains allowed to corroborate, within a single run, the hybrid nature of eculizumab as well as specific subclass domain assignments to the F(ab')2 and Fc regions. Alto-gether, our results confirm the suitability of middle-level CIU of F(ab')2 domains for subclass categorization of canonical and more complex new generation engineered antibodies and related products.
Thomas Botzanowski, Oscar Hernandez-Alba, Martine Malissard, Elsa Wagner-Rousset, Evolène Deslignière, Olivier Colas, Jean-François Haeuw, Alain Beck, Sarah Cianférani

2460 related Products with: Middle level IM-MS and CIU experiments for improved therapeutic immunoglobulin subclass fingerprinting.

1 ml10 mg 100ul100μg 100ul10 ml 125 ml 0.1 mg500 MG100ug Lyophilized

Related Pathways

paperclip

#32452486   2020/05/26 To Up

Rapid and sensitive glycan targeting by lectin-SERS assay.

Glycosylation is an important part of cell signalling that is implicated in many disease states in which glycans play an essential role. Therefore rapid and sensitive differentiation of glycans on proteins is highly desirable. Current technologies for glycan structural analysis normally involve the isolation of glycans from proteins, or enrichment of glycopeptides, and detection by mass spectrometry, which requires relatively large amounts of sample and is not able to be used by non-specialist laboratories. Herein we present a simple and new strategy for targeting the glycans on a protein (with IgG as a model glycoprotein) using surface-enhanced Raman scattering (SERS) coupled to glycan-binding WGA (wheat germ agglutinin) lectin, in a lectin-SERS assay. With one drop (1 μL) of glycoprotein solution, our lectin-SERS assay can detect as low as 10 ng IgG within two hours with high glycan specificity. We extend our technique to examine the surface glycan profiles on two human colorectal cancer cell lines, which show different and unique glycan signatures specific to the target cell lines. Thus, we believe that this method could be potentially used for the real-time and in situ monitoring of glycans on the surface of cells or tissue or in body fluids, and is thus a powerful tool for glycomics research.
Nicole M Cordina, Wei Zhang, Nicolle H Packer, Yuling Wang

1546 related Products with: Rapid and sensitive glycan targeting by lectin-SERS assay.

96 Tests 50 Test100 plates 96 Tests 10 plates100tests400Tests1 kit

Related Pathways

paperclip

#32451213   2020/05/22 To Up

Immunogenicity and protection induced by recombinant Toxocara canis proteins in a murine model of toxocariasis.

Toxocariasis, a natural helminth infection of dogs and cats caused by Toxocara canis and T. cati, respectively, that are transmitted to mammals, including humans. Infection control is based currently on periodic antihelmintic treatment and there is a need for the development of vaccines to prevent this infection.
Luis Fabián Salazar Garcés, Leonardo Freire Santiago, Sara Patrícia de Oliveira Santos, Dumar Alexander Jaramillo Hernández, Marcia Barbosa da Silva, Vitor Dos Santos Alves, Elisania Fontes Silveira, Stella Maria Barrouin-Melo, Philip John Cooper, Luis Gustavo Carvalho Pacheco, Carina da Silva Pinheiro, Neuza Maria Alcantara-Neves

2372 related Products with: Immunogenicity and protection induced by recombinant Toxocara canis proteins in a murine model of toxocariasis.

10 1mg100ul1mg50 100 10.00 ug22101mg1mg

Related Pathways

paperclip

#32450807   2020/05/25 To Up

Immunogenicity and protective efficacy of a live, oral cholera vaccine formulation stored outside-the-cold-chain for 140 days.

Cholera, an acute watery diarrhoeal disease caused by Vibrio cholerae serogroup O1 and O139 across the continents. Replacing the existing WHO licensed killed multiple-dose oral cholera vaccines that demand 'cold chain supply' at 2-8 °C with a live, single-dose and cold chain-free vaccine would relieve the significant bottlenecks and cost determinants in cholera vaccination campaigns. In this direction, a prototype cold chain-free live attenuated cholera vaccine formulation (LACV) was developed against the toxigenic wild-type (WT) V. cholerae O139 serogroup. LACV was found stable and retained its viability (5 × 10 CFU/mL), purity and potency at room temperature (25 °C ± 2 °C, and 60% ± 5% relative humidity) for 140 days in contrast to all the existing WHO licensed cold-chain supply (2-8 °C) dependent killed oral cholera vaccines.
Tew Hui Xian, Kurunathan Sinniah, Chan Yean Yean, Venkateskumar Krishnamoorthy, Mohd Baidi Bahari, Manickam Ravichandran, Guruswamy Prabhakaran

2428 related Products with: Immunogenicity and protective efficacy of a live, oral cholera vaccine formulation stored outside-the-cold-chain for 140 days.

1 mg2 1 mg1000 tests0.1mg 1 G250 mg1 mg100 ug1 mg0.1 mg

Related Pathways

paperclip

#32450768   2020/05/25 To Up

Detection of pseudorabies virus antibody in swine oral fluid using a serum whole-virus indirect ELISA.

We evaluated the detection of pseudorabies virus (PRV) antibodies in swine oral fluid. Oral fluid and serum samples were obtained from 40 pigs allocated to 4 treatment groups (10 pigs/group): negative control (NC); wild-type PRV inoculation (PRV 3CR Ossabaw; hereafter PRV); PRV vaccination (Ingelvac Aujeszky MLV; Boehringer Ingelheim; hereafter MLV); and PRV vaccination followed by PRV inoculation at 21 d post-vaccination (MLV-PRV). Using a serum PRV whole-virus indirect IgG ELISA (Idexx Laboratories) adapted to the oral fluid matrix, PRV antibody was detected in oral fluid samples from treatment groups PRV, MLV, and MLV-PRV in a pattern similar to serum. Vaccination alone produced a low oral fluid antibody response (groups MLV and MLV-PRV), but a strong anamnestic response was observed following challenge with wild-type virus (group PRV). Analyses of the oral fluid PRV indirect IgG ELISA results showed good binary diagnostic performance (area under ROC curve = 93%) and excellent assay repeatability (intra-class correlation coefficient = 99.3%). The demonstrable presence of PRV antibodies in swine oral fluids suggests the possible use of oral fluids in pseudorabies surveillance.
Ting-Yu Cheng, Alexandra Buckley, Albert Van Geelen, Kelly Lager, Alexandra Henao-Díaz, Korakrit Poonsuk, Pablo Piñeyro, David Baum, Ju Ji, Chong Wang, Rodger Main, Jeffrey Zimmerman, Luis Giménez-Lirola

1701 related Products with: Detection of pseudorabies virus antibody in swine oral fluid using a serum whole-virus indirect ELISA.

96T100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100 100ug Lyophilized100100ug Lyophilized50ug100ug Lyophilized100ug Lyophilized

Related Pathways

paperclip

#32450550   2020/04/26 To Up

Eradication of persistent coxsackievirus B infection from a pancreatic cell line with clinically used antiviral drugs.

Persistent enterovirus infections create a difficult therapeutic challenge in immunocompromised patients and may also contribute to the development of chronic diseases including type 1 diabetes, cardiomyopathies, post-polio syndrome and chronic fatigue syndrome.
Anni Honkimaa, Amir-Babak Sioofy-Khojine, Sami Oikarinen, Antoine Bertin, Didier Hober, Heikki Hyöty

2580 related Products with: Eradication of persistent coxsackievirus B infection from a pancreatic cell line with clinically used antiviral drugs.

500ugcase100 plates1 mg1 kit100ul25 ml.100ug100ug1 kit100ug

Related Pathways

paperclip

Error loading info... Pleas try again later.